Mounjaro Cost: Monthly List Price and What Changes It

Mounjaro (tirzepatide) carries an approximate US list price of about $1,080 a month on the figures used across GLPKit. What you actually pay is usually far from that single number, because coverage for its approved use in type 2 diabetes, your pharmacy, your dose stage and the form dispensed all move the total. This page explains each factor in plain language. It is education only.

The headline figure: about $1,080 a month, approximate

Start with the benchmark. The approximate US list price used on this site for Mounjaro is about $1,080 a month, sitting just above Zepbound at about $1,060 and above Ozempic at about $1,000 in the branded comparison. List price is the figure before insurance cost sharing, savings programs or pharmacy cash pricing are applied, so it is best understood as the reference point every other quote is measured against, not as a prediction of your bill. Our GLP-1 price comparison places it beside the other pens.

Mounjaro is a once weekly injection with a published schedule that starts at 2.5 mg and rises by 2.5 mg steps every at least 4 weeks, up to a maximum of 15 mg weekly. Treatment for type 2 diabetes is generally ongoing, so the monthly figure repeats. Reading it as an annual commitment, before any coverage is applied, is the honest way to frame the decision, and the GLP-1 cost calculator will run about $1,080 a month across 6 or 12 months for you.

The diabetes label and why coverage follows it

Mounjaro is FDA approved for type 2 diabetes. That single fact shapes its cost story, because insurance coverage generally follows approved uses. For a person with type 2 diabetes whose plan includes Mounjaro on its formulary, the out of pocket cost after prior authorization, deductible and cost sharing can be far below list price, and manufacturer savings cards may apply for commercially insured patients under the program terms, which generally exclude use with government insurance such as Medicare or Medicaid. For a person without a diabetes diagnosis, coverage is a different and usually harder conversation, because the weight management approval belongs to Zepbound, the other tirzepatide brand.

This is also why prescriptions should not be treated as interchangeable tickets to the cheapest pen. A prescriber documents the diagnosis and the medical reasoning, the plan applies its rules to that use, and the pharmacy fills what was prescribed. If cost is pushing you to ask about a different brand, have that conversation openly with your prescriber. They can explain what your diagnosis supports, what your plan is likely to do, and whether an appeal, a program application or a different medicine is the realistic next step.

Pens, vials and why form matters in general terms

In general terms, Mounjaro is dispensed as single dose pens, where each pen holds one weekly dose at a set strength, so a dose increase means a pen of a different strength rather than a different amount drawn from the same container. Tirzepatide has also been supplied in vial presentations in some settings, where a dose is drawn from a vial with a syringe. The form matters for cost discussions because packaging, strengths and what a pharmacy stocks can affect the cash quote you are given, and because the experience of using the medicine differs: a fixed pen removes measuring, while a vial puts accuracy on the user and their pharmacist's instructions.

Do not convert between forms on your own. The dose your prescriber set is tied to the product and presentation dispensed, and instructions for one form do not transfer automatically to another. If your pharmacy proposes a different presentation, or a compounded tirzepatide vial is offered through a telehealth service instead, that is a prescriber and pharmacist conversation before anything is dispensed. Compounded tirzepatide, advertised from about $379 a month, is not FDA approved, and it is covered in detail on our tirzepatide cost page.

What else moves your monthly total

Pharmacy choice is the quiet variable. Cash prices vary between pharmacies for the same prescription, and even with coverage, which pharmacy network your plan uses can change cost sharing. Dose stage matters less to the branded headline than people expect, but it matters to supply: a dose increase mid month can mean a new prescription and a new dispensing, and missed or paused weeks, for example around surgery, change how many pens you actually use in a period. Follow up visits and lab work your prescriber orders are also part of the real cost of treatment, even though they never appear in the pen price.

Finally, program terms move and expire. Savings cards have eligibility rules and end dates set by the manufacturer, assistance programs verify income and coverage status, and plan formularies are reset, commonly each year. A total that works this year should be rechecked when any of those pieces changes, rather than assumed to continue. Your pharmacist is often the fastest source for the current applied total, and your prescriber's office usually handles prior authorization renewals. Keeping both relationships active is part of affording long term treatment, not an administrative extra.

Planning for a full year of treatment

Because Mounjaro treatment for type 2 diabetes is usually long term, it helps to plan the cost as a yearly pattern rather than a monthly surprise. List the repeating pieces: the pen itself at your applied coverage total, the follow up appointments and lab checks your prescriber schedules, and any other diabetes supplies you use alongside it. Then mark the dates when the pattern can change, such as your plan year resetting, a deductible starting again, or a savings program term ending. Seeing those dates in advance turns a sudden increase at the pharmacy into an expected event you have already discussed with your care team.

It also helps to keep one pharmacy as your main point of contact where you can. A pharmacist who holds your full record can spot a pricing change, explain whether it came from your plan, your dose strength or the pharmacy itself, and contact your prescriber's office when a renewal or authorization is the real problem. That continuity is worth something in a treatment measured in years, and it costs nothing extra to arrange.

Frequently asked questions

Back to all GLPKit guides